GENINUS Inc. (KOSDAQ:389030)

Market Cap	157.23B +258.5%
Revenue (ttm)	10.48B +62.4%
Net Income	-17.37B
EPS	-521.00
Shares Out	33.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	661,286
Average Volume	737,899
Open	4,950.00
Previous Close	4,880.00
Day's Range	4,620.00 - 5,000.00
52-Week Range	1,080.00 - 6,480.00
Beta	0.40
RSI	44.26
Earnings Date	May 15, 2026

About GENINUS

GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It serves hospitals, pharmaceutical companies, and researchers. The company was founded in 2018 and is headquartered in Seoul, South Korea.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 389030

Financial Performance

In 2025, GENINUS's revenue was 10.48 billion, an increase of 62.40% compared to the previous year's 6.46 billion. Losses were -17.37 billion, 41.6% more than in 2024.